Cowen and Company’s iTeos Therapeutics ITOS Stock Holding History

Cowen and Company’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-588,238	Closed	-$20.1M	–	638
2021 Q1	$20.1M	Buy	+588,238	New	+$21.3M	1.38%	12

Other funds holding ITOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cowen and Company's ITOS Position: Q2 2021 in Review

Cowen and Company sold out of iTeos Therapeutics (ITOS) in Q2 2021, closing a stake of 588,238 shares — an estimated $20.1M sold.

Cowen and Company first reported a position in ITOS in Q1 2021 and held it in 1 quarter. The position peaked at $20.1M in Q1 2021. 83 funds tracked by Wall St. Rank hold ITOS as of Q2 2021.

Cowen and Company reported no remaining iTeos Therapeutics position as of Q2 2021 after selling out during the quarter.
Cowen and Company sold 588,238 iTeos Therapeutics shares in Q2 2021, an estimated $20.1M.
Cowen and Company first reported a position in iTeos Therapeutics in Q1 2021 and held it in 1 quarter.
Cowen and Company's iTeos Therapeutics position peaked at $20.1M in Q1 2021.
83 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2021.

Based on Cowen and Company's 13F filing for Q2 2021, filed 13 Aug 2021.